Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Zevra Therapeutics (NASDAQ:ZVRA) will be issuing its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.44) per share for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The company had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same period last year, the firm posted ($0.15) EPS. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

ZVRA opened at $9.00 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The stock has a market capitalization of $473.58 million, a price-to-earnings ratio of -5.36 and a beta of 1.93. The company has a fifty day moving average of $7.89 and a 200 day moving average of $6.35. Zevra Therapeutics has a fifty-two week low of $3.89 and a fifty-two week high of $9.04.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ZVRA. Maxim Group raised their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Monday, September 30th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Finally, JMP Securities assumed coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $20.83.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.